Abstract
Tumoral angiogenesis is mainly an endothelial cell-mediated process, which has been largely demonstrated to take on a crucial role in tumor growth, invasion, and metastasis. Thus, tumor-associated neovasculature represents a pivotal target in cancer therapy. Several mechanisms take part in the genesis of this pathological vasculature, most notably neoangiogenesis and postnatal vasculogenesis. These processes may also play a critical role in the resistance to antiangiogenic agents, leading to tumor progression. In particular, vasculogenesis is mediated by endothelial progenitor cells (EPCs), which include cellular subpopulations with different functional capacities. EPCs are able to proliferate, migrate, and differentiate into mature endothelial cells (ECs) in response to tumor growth, promoting the “angiogenic switch” and, consequently, inducing the invasion and metastases of cancer cells. Therefore, vasculogenesis mediated by EPCs represents an intriguing therapeutic target, both in early and late stages of cancer progression, thereby working as potential landmark for synthesizing novel and more effective anti-angiogenic drugs. Here, we aim to focus and to summarize several biological features of EPCs and EPC-based therapeutic approach with potential translation in human clinical trials.
Keywords: Angiogenesis, cancer, endothelial progenitor cells, therapy.
Current Stem Cell Research & Therapy
Title:Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy
Volume: 10 Issue: 2
Author(s): Michele Ammendola, Christian Leporini, Maria Luposella, Rosario Sacco, Giuseppe Sammarco, Emilio Russo, Rosa Patruno, Giovambattista De Sarro and Girolamo Ranieri
Affiliation:
Keywords: Angiogenesis, cancer, endothelial progenitor cells, therapy.
Abstract: Tumoral angiogenesis is mainly an endothelial cell-mediated process, which has been largely demonstrated to take on a crucial role in tumor growth, invasion, and metastasis. Thus, tumor-associated neovasculature represents a pivotal target in cancer therapy. Several mechanisms take part in the genesis of this pathological vasculature, most notably neoangiogenesis and postnatal vasculogenesis. These processes may also play a critical role in the resistance to antiangiogenic agents, leading to tumor progression. In particular, vasculogenesis is mediated by endothelial progenitor cells (EPCs), which include cellular subpopulations with different functional capacities. EPCs are able to proliferate, migrate, and differentiate into mature endothelial cells (ECs) in response to tumor growth, promoting the “angiogenic switch” and, consequently, inducing the invasion and metastases of cancer cells. Therefore, vasculogenesis mediated by EPCs represents an intriguing therapeutic target, both in early and late stages of cancer progression, thereby working as potential landmark for synthesizing novel and more effective anti-angiogenic drugs. Here, we aim to focus and to summarize several biological features of EPCs and EPC-based therapeutic approach with potential translation in human clinical trials.
Export Options
About this article
Cite this article as:
Ammendola Michele, Leporini Christian, Luposella Maria, Sacco Rosario, Sammarco Giuseppe, Russo Emilio, Patruno Rosa, De Sarro Giovambattista and Ranieri Girolamo, Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy, Current Stem Cell Research & Therapy 2015; 10 (2) . https://dx.doi.org/10.2174/1574888X10666141126113622
DOI https://dx.doi.org/10.2174/1574888X10666141126113622 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry Recent Advances and Patents on Coronary Sinus Perfusion Devices for Treatment of Heart Disease
Recent Patents on Biomedical Engineering (Discontinued) Clinical Applications for Cardiovascular Magnetic Resonance Imaging at 3 Tesla
Current Cardiology Reviews Endothelin and the Ischaemic Heart
Current Vascular Pharmacology An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry The mir-221/222 Cluster is a Key Player in Vascular Biology via the Fine-Tuning of Endothelial Cell Physiology
Current Vascular Pharmacology Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry The Dynamic Progress of Myocardial Infarction Studied by Spectroscopic Techniques
Current Metabolomics Inflammation and Coronary Artery Disease
Current Vascular Pharmacology Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Bid Stands at the Crossroad of Stress-Response Pathways
Current Cancer Drug Targets Mast Cells: Pivotal Players in Cardiovascular Diseases
Current Cardiology Reviews Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Current Medicinal Chemistry Retraction Note: Phytochemicals from Plants to Combat Cardiovascular Disease
Current Medicinal Chemistry Treatment of Inflammatory Diseases with Mesenchymal Stem Cells
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry